Oxidative stress influences CC-chemokine levels in hemodialyzed patients

Nephron - Physiology

Volumn 96, Issue 4, 2004, Pages

  Pawlak, Krystyna ^a,b   Pawlak, Dariusz ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Dept of Nephrology and Int Med ^*  (Poland)

Author keywords

Atherosclerosis; Cardiovascular disease; CC chemokines; Hemodialysis; Oxidative stress

Indexed keywords

AUTOANTIBODY; BETA CHEMOKINE; COPPER ZINC SUPEROXIDE DISMUTASE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; OXIDIZED LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; MEASUREMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; ARTERIOSCLEROSIS; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ARTERIOSCLEROSIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINES, CC; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SUPEROXIDE DISMUTASE;

EID: 2342639671     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077381     Document Type: Article

References (37)

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
2. Magi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-883.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
4. Nguyen A, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985;28:158-167.
5. Toborek M, Wasik T, Drózdz M, Klin M, Manger-Wróbel K, Kopieczna-Grzebieniak E: Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992;41:1229-1232.
6. Mimic - Oka J, Simic T, Djukanovic L, Reljic Z, Davicevic Z: Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 1999;51:233-241.
7. 2α as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 2002;20:537-542.
8. Vitko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
9. Miyata T, Wada Y, Cai Z, Iida Y, Hornie K, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of increased oxidative stress In the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-1181.
10. Tarng DC, Huang TP, Wei YH, Liu TY, Chen HW, Chen TW, Yung WC: 8-hydroxy-2′-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000;36:934-944.
11. Ceballot-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Rad Biol Med 1996;21:845-853.
12. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
13. Rollins BJ: Chemokines. Blood 1997;90:909-928.
14. Furie MB, Gwendalyn JR: Chemokines and tissue injury. Am J Pathol 1995;146:1287-1301.
15. Nelken NA, Cuoghlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-1127.
16. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ: Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994;1:S3-S10.
17. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: modification of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
18. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H: Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000;148:171-177.
19. Bayes B, Cruz Pastor M, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003;18:106-112.
20. Mates JM, Perez-Gomez C, Nunez de Castro I: Antioxidant enzymes and human diseases. Clin Biochem 1999;32:595-603.
21. Futenma A, Yamada H, Kitano M, Miyai H, Fukatsu A, Kato K: Plasma levels of superoxide dismutase and its isomers in patients with chronic renal failure. Nippon Jinzo Gakkai Shi 1993;35:371-376.
22. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002;17:435-441.
23. Jacobson SH, Thylen P, Lundahl J: Three monocyte-related determinants of atherosclerosis in haemodialysis. Nephrol Dial Transplant 2000;15:1414-1419.
24. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996;50:566-570.
25. Aukrust P, Berge RK, Ueland T, Aaser E, Damas JK, Wikeby L, Brunsvig A, Muller F, Forfang K, Froland SS, Gullestad L: Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001;37:485-491.
26. Chandel NS, Trzyna WC, McClintock DS, Schumacker PT: Role of oxidants in NF-kB activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol 2000;165:1013-1021.
27. Spittle MA, Hoenich NA, Handelman GJ, Adhicarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001;38:1404-1413.
28. Donica H, Kozioł-Montewka M, Ksia̧zek A, Starosławska E: Evaluation of immunoglobulins, proinflammatory cytokines and lipid concentrations in patients with diabetic nephropathy treated with continual ambulatory peritoneal dialysis (CAPD). Ann Univ Mariae Curie-Skłodowska [Med] 2000;55:73-79.
29. Corsi MM, Leone G, Fulgenzi A, Wasserman K, Leone F, Ferrero ME: RANTES and MCP-1 chemokine plasma levels in chronic renal transplant dysfunction and chronic renal failure. Clin Biochem 1999;32:455-460.
30. Hariharan D, Ho W, Cutilli J, Campbell DE, Douglas SD: CC-chemokine profile of cord blood mononuclear cells: Selective defect in RANTES production. Blood 2000;95:715-718.
31. Malmberg K-J, Arulampalam V, Ichihara F, Petterson M, Seki K, Andersson T, Lenkei R, Masucci G, Pettersson S, Kiessling R: Inhibition of activated/memory (CD45RO+) T cells by oxidative stress associated with block of NF-κB activation. J Immunol 2001;167:2595-2601.
32. Genin P, Algarte M, Roof P, Lin R, Hiscott J: Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription factors. J Immunol 2000;164:5352-5361.
33. Lane BR, Markovitz DM, Woodford NL, Rochword R, Strieter RM, Coffey MJ: TNF-alpha inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing CC-chemokine receptor 5 (CCR5) expression. J Immunol 1999;163:3653-3661.
34. Inal M, Kanbak G, Sen S, Akyuz F, Sunal E: Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-Vitamin E combined therapy. Free Radic Res 1999;31:211-216.
35. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H: Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000;53(suppl 1):30-35.
36. De Marchi S, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997;8:1147-1156.
37. Aguilera A, Bajo MA, Diez JJ, Ruiz-Caravasca ML, Vicenta Cuesta M, Alvarez V, Codoceo R, Selgas R: Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients. Adv Perit Dial 2002;18:200-205.